Successful treatment of polymicrobial calcaneal osteomyelitis with telavancin, rifampin, and meropenem

Annals of Pharmacotherapy

Volumn 46, Issue 6, 2012, Pages

  Brinkman, Mary Beth ^a   Fan, Kaili ^b   Shiveley, Renee L ^c   van Anglen, Lucinda J ^d  

^a UNIVERSITY OF HOUSTON   (United States)

^b Infectious Disease Specialist   (United States)

^c Clinical Pharmacy Manager   (United States)

^d Healix Infusion Therapy   (United States)

Author keywords

Calcaneal infection; Meropenem; Osteomyelitis; Telavancin

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CIPROFLOXACIN; DAPTOMYCIN; ERTAPENEM; GRANULOCYTE COLONY STIMULATING FACTOR; MEROPENEM; MINOCYCLINE; RIFAMPICIN; SULFAMETHOXAZOLE; TELAVANCIN; TETRACYCLINE; TRIMETHOPRIM; VANCOMYCIN;

ADULT; ANOREXIA; ANTIBIOTIC THERAPY; ARTICLE; CALCANEUS; CASE REPORT; DRUG WITHDRAWAL; DYSGEUSIA; GAIT DISORDER; HEEL; HUMAN; LEUKOPENIA; MALE; MENINGOMYELOCELE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; NEUROGENIC BLADDER; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOMYELITIS; POLYMICROBIAL CALCANEAL OSTEOMYELITIS; PRIORITY JOURNAL; SKIN INDURATION; SPINA BIFIDA; TREATMENT DURATION; WOUND HEALING;

ADOLESCENT; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; COINFECTION; DRUG THERAPY, COMBINATION; HUMANS; MALE; OSTEOMYELITIS; RIFAMPIN; STAPHYLOCOCCAL INFECTIONS; THIENAMYCINS; TREATMENT OUTCOME;

EID: 84862267308     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q331     Document Type: Article

References (41)

1. Mader JT, Shirtliff M, Calhoun JH. Staging and staging application in osteomyelitis. Clin Infect Dis 1997;25:1303-1309.
2. Dagan R. Management of acute hematogenous osteomyelitis and septic arthritis in the pediatric patient. Pediatr Infect Dis J 1993;12:88-92.
3. Johnston B, Conly J. Osteomyelitis management: more art than science? Can J Infect Dis Med Microbiol 2007;18:115-118.
4. Granick M, Boykin J, Gamelli R, Schultz G, Tenenhaus M. Toward a common language: surgical wound bed preparation and debridement. Wound Repair Regen 2006;14(suppl 1):S1-S10. DOI 10.1111/j.1743-6109.2005.00096.x
5. Diekema DJ, Pfaller MA, Schmitz FJ, et al. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001;32(suppl 2):S114-S132. DOI 10.1086/320184
6. Lew DP, Waldvogel FA. Osteomyelitis. N Engl J Med 1997;336:999-1007.
7. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function- measured and estimated glomerular filtration rate. N Engl J Med 2006;354:2473-83. DOI 10.1056/NEJMra054415
8. Norden CW, Bryant R, Palmer D, Montgomerie JZ, Wheat J. Chronic osteomyelitis caused by Staphylococcus aureus: controlled clinical trial of nafcillin therapy and nafcillin-rifampin therapy. South Med J 1986;79:947-951.
9. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-245.
10. Black E, Lau TTY, Ensom MHH. Vancomycin-induced neutropenia: is it dose-or duration-related? Ann Pharmacother 2011;45:629-638. DOI 10.1345/aph.1P583
11. O'Grady NP, Alexander M, Burns LA, et al. Guidelines for the prevention of intravascular catheter-related infections. Am J Infect Control 2011;39:S1-S34. DOI 10.1016/j.ajic.2011.01.003
12. Lipsky BA, Berendt AR, Deery HG, et al. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2004;39:885-910. DOI 10.1086/424846
13. Lee MC, Tashjian RZ, Eberson CP. Calcaneus osteomyelitis from community- acquired MRSA. Foot Ankle Int 2007;28:276-280. DOI 10.3113/FAI.2007.0276
14. Lew DP, Waldvogel FA. Osteomyelitis. Lancet 2004;364:369-379. DOI 10.1016/S0140-6736(04)16727-5
15. Patti JM, Boles JO, Hook M. Identification and biochemical characterization of the ligand binding domain of the collagen adhesin from Staphylococcus aureus. Biochemistry 1993;32:11428-11435.
16. Anstead GM, Quinones-Nazario G, Lewis JS 2nd. Treatment of infections caused by resistant Staphylococcus aureus. Methods Mol Biol 2007;391:227-258.
17. Arnold SR, Elias D, Buckingham SC, et al. Changing patterns of acute hematogenous osteomyelitis and septic arthritis: emergence of community- associated methicillin-resistant Staphylococcus aureus. J Pediatr Orthop 2006;26:703-708.
18. Armstrong DG, Lanthier J, Lelievre P, Edelson GW. Methicillin-resistant coagulase-negative staphylococcal osteomyelitis and its relationship to broad-spectrum oral antibiosis in a predominantly diabetic population. J Foot Ankle Surg 1995;34:563-566.
19. John JF, Harvin AM. History and evolution of antibiotic resistance in coagulase- negative staphylococci: susceptibility profiles of new antistaphylococcal agents. Ther Clin Risk Manag 2007;3:1143-1152.
20. Rupp ME, Archer GL. Coagulase-negative staphylococci: pathogens associated with medical progress. Clin Infect Dis 1994;19:231-43;quiz 44-5.
21. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillinresistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011;52:e18-e55. DOI 10.1093/cid/ciq146
22. Soriano A, Marco F, Martinez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008;46:193-200. DOI 10.1086/524667
23. Darley ES, MacGowan AP. Antibiotic treatment of gram-positive bone and joint infections. J Antimicrob Chemother 2004;53:928-35.
24. Davis JS. Management of bone and joint infections due to Staphylococcus aureus. Intern Med J 2005;35:S79-S96. DOI 10.1111/j.1444-0903.2005.00982.x
25. Lai KK, Kleinjan J, Belliveau P. Vancomycin-induced neutropenia treated with granulocyte colony-stimulating factor during home intravenous infusion therapy. Clin Infect Dis 1996;23:844-845.
26. Mader JT, Adams K. Comparative evaluation of daptomycin (LY146032) and vancomycin in the treatment of experimental methicillin-resistant Staphylococcus aureus osteomyelitis in rabbits. Antimicrob Agents Chemother 1989;33:689-692.
27. Dhand A, Bayer AS, Pogliano J, et al. Use of antistaphylococcal {beta}- lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin Infect Dis 2011;53:158-163. DOI 10.1093/cid/cir340
28. Marty FM, Yeh WW, Wennersten CB, et al. Emergence of a clinical daptomycin- resistant Staphylococcus aureus isolate during treatment of methicillin- resistant Staphylococcus aureus bacteremia and osteomyelitis. J Clin Microbiol 2006;44:595-597. DOI 10.1128/JCM.44.2.595-597.2006
29. Product information. Vibativ (telavancin). Deerfield, IL: Astellas Pharma US, Inc, 2009.
30. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005;41:1373-1406. DOI 10.1086/497143
31. Attwood RJ, LaPlante KL. Telavancin: a novel lipoglycopeptide antimicrobial agent. Am J Health Syst Pharm 2007;64:2335-2348. DOI 10.2146/ajhp070080
32. Wilson SE, O'Riordan W, Hopkins A, Friedland HD, Barriere SL, Kitt MM. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections associated with surgical procedures. Am J Surg 2009;197:791-796. DOI 10.1016/j.amjsurg.2008.05.012
33. Mendes RE, Sader HS, Jones RN. Activity of telavancin and comparator antimicrobial agents tested against Staphylococcus spp. isolated from hospitalised patients in Europe (2007-2008). Int J Antimicrob Agents 2010;36:374-379. DOI 10.1016/j.ijantimicag.2010.05.016
34. Yin LY, Calhoun JH, Thomas TS, Wirtz ED. Efficacy of telavancin in the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis: studies with a rabbit model. J Antimicrob Chemother 2009;63:357-360. DOI 10.1093/jac/dkn490
35. Landersdorfer CB, Bulitta JB, Kinzig M, Holzgrabe U, Sorgel F. Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations. Clin Pharmacokinet 2009;48:89-124.
36. Twilla JD, Gelfand MS, Cleveland KO, Usery JB. Telavancin for the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis. J Antimicrob Chemother 2011;66:2675-2677.
37. Stryjewski ME, Graham DR, Wilson SE, et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis 2008;46:1683-1693. DOI 10.1086/587896
38. Dalhoff A. Quinolone resistance in Pseudomonas aeruginosa and Staphylococcus aureus. Development during therapy and clinical significance. Infection 1994;22(suppl 2):S111-S121.
39. Paterson DL. The epidemiological profile of infections with multidrugresistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 2006;43(suppl 2):S43-S48. DOI 10.1086/504476
40. Treatment options for selected highly resistant bacteria. In: Gilbert DN, Moellering RC, Eliopoulous GM, Chambers HF, Saag MS. The Sanford guide to antimicrobial therapy 2010. 40th ed. Dallas, TX: Antimicrobial Therapy, 2010:73.
41. Rubino C, Figus A, Mazzocchi M, Dessy LA, Martano A. The propeller flap for chronic osteomyelitis of the lower extremities: a case report. J Plas Reconstr Aesthet Surg 2009;62:e401-e404.